Company news
Whitehawk Therapeutics, Inc. news in 2022
Whitehawk Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
November 16, 2022
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
November 8, 2022
Aadi Bioscience Announces Planned Leadership Transition
November 7, 2022
Aadi Bioscience to Present at Upcoming Investor Conferences
November 2, 2022
Aadi Bioscience to Report Third Quarter 2022 Results and Corporate Update
November 1, 2022
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation
October 11, 2022
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
September 21, 2022
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences
August 31, 2022
Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update
August 9, 2022
Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update
July 27, 2022
Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes
June 22, 2022
Aadi Bioscience to Present at the Jefferies Global Healthcare Conference
May 31, 2022
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications
May 30, 2022
Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting
May 25, 2022
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022
Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 11, 2022
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
May 8, 2022
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
May 3, 2022
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
April 27, 2022
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
April 17, 2022
Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)
April 7, 2022
Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes
March 30, 2022
Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 16, 2022
Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen’s 42nd Annual Health Care Conference
February 28, 2022
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
February 22, 2022
Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
January 3, 2022